News
Deep Analysis of Bo Lun
It has currently obtained the following honorary titles: Top 10 Chinese Pharmaceutical Outsourcing Companies, Top 10 Most Competitive Enterprises in China's Pharmaceutical Service Industry, National-level "Little Giant" Enterprise Specialized in Specialized, Refined, Differential and Innovative Fields, Guangdong Provincial-level Enterprise Technology Center, Guangdong Postdoctoral Innovation and Practice Base, Top 50 Most Investment-Worthy Enterprises in China, and Honorary Director Unit of the CRO Branch of China Pharmaceutical Quality Management Association (CPQMA).
Deep Analysis of Bo Lun
Deep Analysis of Bo Lun
2026-09-20
Overseas Commercialization: Dilemmas and Solutions in Global Oncology Clinical Trials of Innovative Anticancer Drugs
2026-06-22
The Quiet War Over “Standards”: How Wide Are the CMC Gaps Between China, the US, and Europe?
2026-06-08
From Tedious Manual Search to AI-Assisted Precision Guidance: BojiMed Reveals the Intelligent Breakthrough in MedDRA Coding
2026-06-16
The Shoe Has Dropped: FDA's New Guidance Loosens Animal-Testing Requirements for Oncology Drug Development
2026-05-25
An AI-Based Analysis of 420 CRLs: What Is the FDA Actually Rejecting?
2026-05-06
FDA'sReal-TimeClinicalTrial(RTCT)PilotProgram: RegulatoryFramework,Drivers,andImplicationsfor ChineseBiopharmaceuticalCompanies
2026-07-29
The Dual Regulatory Era Under Decrees 818 and 828: Implementation Pathways for CGT IIT from Unregulated Expansion to Compliant Development
2026-07-22
In-Depth Analysis by BojiMed | Data Illusions and Truth Restoration: The Statistical Logic Behind ISS
2026-07-02
New Drug Development or Technology Commercialization? Selecting the Right R&D Path for CGT Under the Dual-Track Regulatory Framework
2026-07-01